Wockhardt’s manufacturing unit at Daman continues Good Manufacturing Practices as per UK MHRA

14 Dec 2016 Evaluate

UK health regulator -- UK Medicines and Healthcare Products Regulatory Agency (UK MHRA) – has continued the approval status of Wockhardt’s manufacturing unit at Kadaiya, Daman relating to the principles and guidelines of Good Manufacturing Practices (GMP). The said manufacturing unit complies with the principles and guidelines which has now been continued by UK MHRA.

Last month, the company’s step down subsidiary - CP Pharmaceuticals, Wrexham, United Kingdom, had been issued a Warning Letter by the US Food and Drug Administration (USFDA).

Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s, the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.


Wockhardt Share Price

1360.10 28.75 (2.16%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×